1.Progress of medical treatment for thyroid cancer
Journal of International Oncology 2020;47(4):231-235
Thyroid cancer is a common malignant tumor of the head and neck and endocrine system, characterized by high morbidity and low mortality. The main clinical challenge is the treatment of patients with advanced or high-risk thyroid cancer. At present, the study on the molecular pathogenesis of thyroid cancer provide new opportunities for thyroid cancer, including chemotherapy, molecular targeted therapy and immunotherapy.
2.Feasibility of Two-Screw Anterior Fixation for Odontoid Fractures in a Chinese Population:A Morphometric Study Based on Computed Tomography
Yixiang AI ; Dereje Gobena ALEMAYEHU ; Genwen MAO ; Yaping LIANG ; Ran CAO ; Jiale HU ; Yimin YANG ; Zhiwei REN
Clinics in Orthopedic Surgery 2023;15(6):983-988
Background:
To evaluate the feasibility of treating odontoid fractures in the Chinese population with two cortical screws based on computed tomography (CT) scans and describe a new measurement strategy to guide screw insertion in treating these fractures.
Methods:
A retrospective review of cervical computed tomographic scans of 128 patients (aged 18–76 years; men, 55 [43.0%]) was performed. The minimum external transverse diameter (METD), minimum external anteroposterior diameter (MEAD), maximum screw length (MSL), and screw projection back angle (SPBA) of the odontoid process were measured on coronal and sagittal CT images.
Results:
The mean values of METD and MEAD were 10.0 ± 1.1 mm and 12.0 ± 1.0 mm, respectively, in men and 9.2 ± 1.0 mm and 11.0 ± 1.0 mm, respectively, in women. Both measurements were significantly higher in men (p < 0.001). In total, 87 individuals (68%) had METD > 9.0 mm that could accommodate two 3.5-mm cortical screws. The mean MSL value and SPBA range were 34.4 ± 2.9 mm and 13.5°–24.2°, respectively, with no statistically significant difference between men and women.
Conclusions
The insertion of two 3.5-mm cortical screws was possible for anterior fixation of odontoid fractures in 87 patients (68%) in our study, and there was a statistically significant difference between men and women.
3.Discovery of a new nosiheptide-producing strain and its fermentation optimization for nosiheptide production
Qihang SUN ; Yuncong XU ; Lingrui WU ; Jiale RONG ; Yanwen WANG ; Yudan CAO ; Chen LUO ; Xuri WU
Journal of China Pharmaceutical University 2022;53(6):725-733
Nosiheptide is a typical thiopeptide antibiotic displaying potent activity toward various drug-resistant strains of Gram-positive pathogens.Although nosiheptide lacks in vivo activity, and good water-solubility with a series of uncontrollable analogues, which may limit its clinical application, glycosylated analogues may overcome problem of low activity and may improve its druggability.In search of novel glycosylated nosiheptide producers, we applied a genome mining strategy that identified Actinoalloteichus sp.AHMU CJ021 that contains all genes required.However, despite the presence of a predicted glycosyltransferase, glycosylated derivatives of nosiheptide were not detected, after following one strain many compounds (OSMAC) strategy and heterologous expression of a regulatory protein NocP.Nevertheless, nosiheptide produced by this strain was remarkably pure, and further experiments were conducted to improve its production by optimization of the culture medium.Under optimal conditions, 58.73 mg/L nosiheptide was produced, representing an almost 6-fold improvement compared to the original fermentation medium.Therefore, we consider Actinoalloteichus sp.AHMU CJ021 a suitable potential candidate for industrial production of nosiheptide, which provides the basis for solving the problem of nosiheptide structural analogues.
4.Construction of fluorescent transgenic zebrafish Tg (ttn.2: EGFP).
Jiale CHEN ; Qiuxiang CAO ; Hui CAO ; Xiangding CHEN ; Yun DENG
Chinese Journal of Biotechnology 2023;39(4):1804-1814
In order to develop a transgenic zebrafish line with green fluorescent protein (enhanced green fluorescent protein, EGFP) expressed specifically in muscle and heart, the recombinant expression vector constructed using the zebrafish ttn.2 gene promoter fragment and EGFP gene coding sequence and the capped mRNA of Tol2 transposase were co-injected into the zebrafish 1-cell stage embryos. The stable genetic Tg (ttn.2: EGFP) transgenic zebrafish line was successfully developed by fluorescence detection, followed by genetic hybridization screening and molecular identification. Fluorescence signals and whole-mount in situ hybridization showed that EGFP expression was located in muscle and heart, the specificity of which was consistent with the expression of ttn.2 mRNA. Inverse PCR showed that EGFP was integrated into chromosomes 4 and 11 of zebrafish in No. 33 transgenic line, while integrated into chromosome 1 in No. 34 transgenic line. The successful construction of this fluorescent transgenic zebrafish line, Tg (ttn.2: EGFP), laid a foundation for the research of muscle and heart development and related diseases. In addition, the transgenic zebrafish lines with strong green fluorescence can also be used as a new ornamental fish.
Animals
;
Zebrafish/genetics*
;
Animals, Genetically Modified/genetics*
;
Green Fluorescent Proteins/metabolism*
;
Zebrafish Proteins/genetics*
;
Promoter Regions, Genetic
5.Herbal Textual Research on Linderae Radix in Famous Classical Formulas
Fen CHENG ; Jiale CAO ; Yichen YANG ; Erhuan WANG ; Hui CHANG ; Cunde MA ; Zhilai ZHAN
Chinese Journal of Experimental Traditional Medical Formulae 2023;29(17):75-87
By reviewing the ancient and modern literature, the name, origin, medicinal parts and other aspects of Linderae Radix in famous classical formulas were systematically sorted out, so as to provide a basis for development of famous classical formulas containing this herb. Linderae Radix was first recorded in Bencao Shiyi in the Tang dynasty under name of Pangqi, and since Rihuazi Bencao of the Five dynasties, all generations of materia medica have used Wuyao as its proper name of the herb. The mainstream source of Linderae Radix used in the past dynasties is dried tuberous roots of Lindera aggregata contained in the 2020 edition of Chinese Pharmacopoeia. The origins of Linderae Radix recorded in the past dynasties are mainly Guangdong, Guangxi, Hunan, Zhejiang, Anhui and others, since the Song dynasty, Tiantai county in Zhejiang province has been regarded as the authentic producing place, in modern times, it is still the authentic place of origin. At harvesting, in ancient times, the harvesting time of the roots was mostly in August, while in modern times, Linderae Radix is mostly harvested in winter and spring or throughout the year, and is dried directly after harvesting or cut thin slices and dried in the place of production. At processing, Linderae Radix was processed by removing the peel and heart, wine roasting, vinegar roasting and other methods in ancient times, and in modern times, it is mostly used in raw form as medicine. In conclusion, it is suggested that the processing method of fresh slicing and drying in the place of origin in the 2020 edition of Chinese Pharmacopoeia should be adopted if Linderae Radix is involved in the development of famous classical formulas.